A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan Claire F. VerschraegenAndrzej P. KudelkaR. De Jager Original Article Pages: 1 - 7
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan Claire F. VerschraegenAndrzej P. KudelkaR. De Jager Original Article 28 October 2003 Pages: 1 - 7
Amifostine induces anaerobic metabolism and hypoxia-inducible factor 1α Michael I. KoukourakisAlexandra GiatromanolakiAdrian L. Harris Original Article Pages: 8 - 14
Amifostine induces anaerobic metabolism and hypoxia-inducible factor 1α Michael I. KoukourakisAlexandra GiatromanolakiAdrian L. Harris Original Article 22 October 2003 Pages: 8 - 14
Synergistic effects of co-administration of angiotensin 1–7 and Neupogen on hematopoietic recovery in mice Dolph D. EllefsonGere S. diZeregaKathleen E. Rodgers Original Article Pages: 15 - 24
Synergistic effects of co-administration of angiotensin 1–7 and Neupogen on hematopoietic recovery in mice Dolph D. EllefsonGere S. diZeregaKathleen E. Rodgers Original Article 16 October 2003 Pages: 15 - 24
Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study Giuseppe FrasciPasquale ComellaGiuseppe Comella Original Article Pages: 25 - 32
Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study Giuseppe FrasciPasquale ComellaGiuseppe Comella Original Article 26 September 2003 Pages: 25 - 32
Citrate enhances the protective effect of orally administered bismuth subnitrate against the nephrotoxicity ofcis-diamminedichloroplatinum Yukihiro KondoSeiichiro HimenoNobumasa Imura Original Article Pages: 33 - 38
Citrate enhances the protective effect of orally administered bismuth subnitrate against the nephrotoxicity of cis-diamminedichloroplatinum Yukihiro KondoSeiichiro HimenoNobumasa Imura Original Article 07 October 2003 Pages: 33 - 38
Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates Jamie RenbargerAlexander AleksicSusan Blaney Original Article Pages: 39 - 42
Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates Jamie RenbargerAlexander AleksicSusan Blaney Original Article 09 October 2003 Pages: 39 - 42
Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo Erling T. DonnellyMarianne KelleySara Rockwell Original Article Pages: 43 - 50
Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo Erling T. DonnellyMarianne KelleySara Rockwell Original Article 22 October 2003 Pages: 43 - 50
Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease Vania T. M. HungriaMaria C. LatrilhaRaul C. Maranhão Original Article Pages: 51 - 60
Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease Vania T. M. HungriaMaria C. LatrilhaRaul C. Maranhão Original Article 22 October 2003 Pages: 51 - 60
Increased myelotoxicity of idarubicin: Is there a pharmacological basis? Frank KroschinskyEberhard SchleyerMarkus Schaich Original Article Pages: 61 - 67
Increased myelotoxicity of idarubicin: is there a pharmacological basis? Frank KroschinskyEberhard SchleyerMarkus Schaich Original Article 03 September 2003 Pages: 61 - 67
Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line Kohkichi HataMitsuhiko OsakiKohji Miyazaki Original Article Pages: 68 - 74
Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line Kohkichi HataMitsuhiko OsakiKohji Miyazaki Original Article 21 October 2003 Pages: 68 - 74
Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study Serafín MoralesAntonio LorenzoCristina Llorca Original Article Pages: 75 - 81
Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study Serafín MoralesAntonio LorenzoCristina Llorca Original Article 14 October 2003 Pages: 75 - 81
Quercetin inhibits the invasion of murine melanoma B16-BL6 cells by decreasing pro-MMP-9 via the PKC pathway Xian-Ming ZhangShao-Peng HuangQiang Xu Original Article Pages: 82 - 88
Quercetin inhibits the invasion of murine melanoma B16-BL6 cells by decreasing pro-MMP-9 via the PKC pathway Xian-Ming ZhangShao-Peng HuangQiang Xu Original Article 30 October 2003 Pages: 82 - 88
Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis, trabectedin) Gianluca TognonRoberta FrapolliMaurizio D'Incalci Short Communication Pages: 89 - 90
Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis, trabectedin) Gianluca TognonRoberta FrapolliMaurizio D’Incalci Short Communication 28 October 2003 Pages: 89 - 90
Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent Patricia E. SchroederKenneth Francis HoflandBrian B. Hasinoff Short Communication Pages: 91 - 93
Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent Patricia E. SchroederKenneth Francis HoflandBrian B. Hasinoff Short Communication 22 October 2003 Pages: 91 - 93
